Ram C V, Gonzalez D G, Kaplan N M, Ralakis J M, Henderson J D, Lugo C E, Zachariah N
Internal Medicine, University of Texas Health Science Center, Dallas.
J Cardiovasc Pharmacol. 1987;10 Suppl 3:S78-80.
Ketanserin is a novel agent that has been shown to be a specific 5-HT2-serotonergic antagonist. It has useful antihypertensive properties. Owing to its unique mechanism of action, it has been suggested that ketanserin may have a favorable effect on tissue blood flow during chronic therapy for hypertension. This double-blind study was designed to evaluate the acute (1 week) and chronic (8 weeks) effects of ketanserin on renal hemodynamic parameters and renin-aldosterone axis in patients with uncomplicated hypertension. Compared to placebo, ketanserin caused a significant blood pressure reduction at the end of the 8-week study period. Despite the reduction in systematic arterial pressure, glomerular filtration rate and renal plasma flow were preserved. Ketanserin therapy induced a slight reduction in plasma renin activity and a marginal increase in the sodium excretion. Although the results of this study are limited by the small number of patients, it appears that ketanserin may have favorable renal hemodynamic effects in uncomplicated essential hypertension.
酮色林是一种新型药物，已被证明是一种特异性5-羟色胺2-血清素能拮抗剂。它具有有效的降压特性。由于其独特的作用机制，有人提出酮色林在高血压的长期治疗中可能对组织血流有有益影响。这项双盲研究旨在评估酮色林对单纯性高血压患者肾血流动力学参数和肾素-醛固酮轴的急性（1周）和慢性（8周）影响。与安慰剂相比，在8周研究期结束时，酮色林使血压显著降低。尽管系统性动脉压降低，但肾小球滤过率和肾血浆流量得以保留。酮色林治疗使血浆肾素活性略有降低，钠排泄略有增加。尽管这项研究的结果因患者数量较少而受到限制，但酮色林在单纯性原发性高血压中似乎可能具有有益的肾血流动力学作用。
